ISRAEL DAYBOOK: Teva Profit Rises on Cephalon Purchase

(Corrects name of company in first paragraph.)

Teva Pharmaceutical Industries Ltd. (TEVA) said fourth-quarter profit rose 23 percent, boosted by last year’s acquisition of U.S. drugmaker Cephalon Inc.

Earnings excluding some costs climbed to $1.4 billion, or $1.59 a share, from $1.1 billion, or $1.25, a year earlier, the Petach Tikva, Israel-based company said in a statement today. Profit matched the average estimate of $1.59 a share from 25 analysts surveyed by Bloomberg.

     WHAT TO WATCH:
* The Central Bureau of Statistics will release consumer price
index data for January at 6:30 p.m. in Jerusalem.
* The Institute for National Security Studies is scheduled to
hold a panel on: “Israel and the US: National Security
Challenges and their Influence on Bilateral Relations” at 4
p.m. in Jerusalem.

     EQUITY MOVERS:
* Nice Systems Ltd. (NICE IT), the maker of digital surveillance
and monitoring systems will probably report adjusted net income
of $133 million for 2011, according to the median estimate of
six analysts surveyed by Bloomberg.
* Nova Measuring Instruments Ltd. (NVMI IT), a maker of
monitoring systems for the semiconductor manufacturing industry,
is scheduled to release fourth-quarter results.
* Delek Real Estate Ltd. (DLKR IT) Series Heh bondholders of the
property company owned by Isaac Tshuva didn’t approve a request
for a delay in interest payments.

     MARKETS:
* The TA-25 Index fell 0.6 percent to 1,112.64.
* The yield on the Mimshal Shiklit government bond due January
2022 was at 4.6 percent.
* The shekel gained 0.3 percent to 3.7290 a dollar at 8:22 a.m.
in Tel Aviv.
* Corn for March delivery rose 0.2 percent to $6.3475 a bushel.
* Crude oil for March delivery increased 0.9 percent to $101.60
a barrel.
* Gold for immediate delivery advanced 0.4 percent to $1,726.38
an ounce.

To contact the reporters on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net; Sharon Wrobel in Tel Aviv at swrobel4@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.